Thera-SAbDab

INFLIXIMAB

>   Structural Summary
TherapeuticInfliximab
TargetTNF/TNFA
Heavy ChainEVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSS
Light ChainDILLTQSPAILSVSPGERVSFSCRASQFVGSSIHWYQQRTNGSPRLLIKYASESMSGIPSRFSGSGSGTDFTLSINTVESEDIADYYCQQSHSWPFTFGSGTNLEVK
100% seqID Fv Structure4g3y [Fvs: HL], 5vh3 [Fvs: AB, HL], 5vh4 [Fvs: AB, HL], 6ugs [Fvs: AB, HL], 6ugt [Fvs: AB, HL], 6ugu [Fvs: AB, HL], 6ugv [Fvs: AB, HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Feb '25)Approved
Estimated Status (Feb '25)NFD
Recorded Developmental Technology
INN Year Proposed1997
INN Year Recommended1998
Companies InvolvedCentocor, Janssen Biotech, Merck & Co, Mitsubishi Tanabe Pharma Corporation, National Jewish Medical and Research Center, Xian-Janssen
Conditions ApprovedAnkylosing spondylitis, Behcet's syndrome, Crohn's disease, Mucocutaneous lymph node syndrome, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Rheumatoid arthritis, Ulcerative colitis
Conditions Activena
Conditions DiscontinuedBerylliosis, Hepatitis C, Pyoderma
NotesDanvilostomig Fv1;Ipilimumab; Sovipostobart; and Tazlestobart all have the same sequence. Likely biosimilars.

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy